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Open access under the ElsThe biological activities of a series of mesoionic 1,3,4-thiadiazolium-2-aminide derivatives have been
studied. The most active compounds (MI-HH; MI-3-OCH3; MI-4-OCH3 and MI-4-NO2) were evaluated
to determine their effect on trypanothione reductase (TryR) activity in Leishmania sp. and Trypanosoma
cruzi. Among the assayed compounds, only MI-4-NO2 showed enzyme inhibition effect on extracts from
different cultures of parasites, which was conﬁrmed using the recombinant enzyme from T. cruzi (TcTryR)
and Leishmania infantum (LiTryR). The enzyme kinetics determined with LiTryR demonstrated a non-com-
petitive inhibition proﬁle of MI-4-NO2. A molecular docking study showed that the mesoionic compounds
could effectively dock into the substrate binding site together with the substrate molecule. The mesoionic
compounds were also effective ligands of the NADPH and FAD binding sites and the NADPH binding site
was predicted as the best of all three binding sites. Based on the theoretical results, an explanation at the
molecular level is proposed for the MI-4-NO2 enzyme inhibition effect. Given TryR as a molecular target,
it is important to continue the study of mesoionic compounds as part of a drug discovery campaign
against Leishmaniasis or Chagas’ disease.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Parasitic protozoa of the family Trypanosomatidae are the caus-
ative agents of many signiﬁcant tropical diseases, including African
trypanosomiasis, Chagas’ disease, and Leishmaniasis. Trypanosoma
cruzi is a protozoan parasite from the order Kinetoplastida that
causes Chagas’ disease. As a result of sustained campaigns of vector
control, the number of new infections in endemic areas has de-
creased, but the disease still affects 16–18 million people in Latin
America and belongs to the group of neglected diseases as deﬁned
by the World Health Organization (WHO).1 Only two drugs,
nifurtimox and benznidazol, are currently available to treat this
disease, and these remain unsatisfactory due to their toxic side
effects and limited efﬁcacy in the chronic phase of the infection.2,3
Leishmaniasis is caused by numerous parasitic protozoan subspe-
cies of the genus Leishmania and is endemic in 88 countries on four
continents. In Brazil, the number of cases has been increasing, both
in magnitude and geographic expansion.4 Leishmaniasis covers as).
evier OA license.variety of forms, from cutaneous ulcers, which causes self-healing
lesions, to visceral leishmaniasis, which is fatal if left untreated.
Among the different therapeutic alternatives available for leish-
maniasis, the WHO recommends the pentavalent antimonies as
ﬁrst-choice medicines, primarily meglumine antimoniate.5,6 An in-
crease in the incidence of drug resistance has been reported,
requiring the use of prohibitively expensive drugs, such as liposo-
mal amphotericin B.5 The currently available chemotherapeutic
agents against these diseases are still inadequate. Hence, there is
an urgent need for the development of new, cost-effective drugs
with minimal side effects. Therefore, the identiﬁcation of new tar-
gets for anti-trypanosomatids is incredibly important.7
The enzyme trypanothione reductase (TryR) was described in
19858 and is a validated drug target in trypanosomatids, as it
was shown to be essential for the survival of these parasites by
protecting them against oxidative stress.8,9 This enzyme is depen-
dent on NADPH and catalyzes the reduction of trypanothione
disulﬁde [T(S)2] dithiol to trypanothione [T(S)2], triggering a cas-
cade of events responsible for the neutralization of reactive
oxygen species.9 In addition to playing a pivotal role in the para-
site, another characteristic that makes TryR a potential target for
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tathione reductase (GR), the enzyme with the corresponding func-
tion in humans.10,11
The chemistry of mesoionic rings, especially their use as
masked dipoles, has been a fruitful area of research since the late
50s.12 Mesoionic compounds are a special class of heterocycles
with special features that contribute to several biological activities.
They possess a betaine-like character with a partial positive charge
on the heterocyclic ring, which generally includes ﬁve members
and is balanced by a negative charge located on an exocyclic
atom.12,13 The large separation between the charged regions leads
lo large dipole moments of about 4–5 D.12,14 These properties sug-
gest the possibility of interactions with biomolecules such as pro-
teins and DNA, and the overall neutral character of these
compounds enables them to cross biological membranes.
Our previous studies have proven that mesoionic derivatives of
the 1,3,4-thiadiazolium-2-aminide class inhibit the in vitro growth
of Leishmania amazonensis, Leishmania braziliensis, Leishmania
chagasi15,16 and Trypanosoma cruzi.17 The activity of two mesoionic
derivatives on the L. amazonensis infection in BALB/c mice,
including the decrease of lesion size and parasitic load, has also
been reported.18 However, other biological activities have been
revealed, including anti-inﬂammatory, analgesic, antibacterial,
antifungal, and antitumor activities.18–21 To continue our study of
mesoionic compounds, especially our investigation into the mech-
anism of action, we sought to elucidate the target of mesoionic
derivatives on Leishmania sp. and Trypanosoma cruzi. Three species
of Leishmania were selected to this work, two species native to the
New World, Leishmania (L) amazonensis and Leishmania (V) brazili-
ensis, and another native to the Old World, Leishmania (L) infantum.
The effects of mesoionic derivatives (Fig. 1) on TryR from parasite
extracts and on recombinant enzymes from L. infantum and T. cruzi
were evaluated.
2. Materials and methods
2.1. Parasites
Parasites of L. infantum (MHOM/MA67ITMAP263 strain) were
used in all experiments. L. amazonensis (MHOM/BR/LTB0016 strain),
L. braziliensis (MCAN/BR/98/R619) and T. cruzi (Y strain) were used
to obtain soluble parasite extracts to analyze the effects ofmesoion-
ic derivatives on TryR.
2.2. Leishmania sp. cultivation
L. infantum promastigotes were cultivated in RPMI medium
(GlutaMAX, Invitrogen) at 26 C and supplemented with 10% fetal
calf serum (FCS). L. amazonensis promastigotes were cultivated in
Schneider’s Drosophila medium, pH 7.2, supplemented with
2 mm L-glutamine, 50 mm HEPES, 35 U/mL penicillin, 35 lg/L
streptomycin, 2% human urine, and 10% FCS, at 27 C in a Biochem-Cl-NN
S N
H
Y
X
Figure 1. Chemical structures of mesoionic derivaistry Oxygen Demand (BOD) incubator. L. braziliensis promastigotes
were cultivated at the same conditions but with 20% FCS.
2.3. Trypanosoma cruzi cultivation
Epimastigote forms of the Y strain of T. cruziwere maintained in
liver infusion tryptose (LIT) medium, pH 7.2, supplemented with
10% FCS and maintained at 27 C in a BOD incubator.22,23 The epim-
astigotes were passaged weekly.
2.4. Soluble extract preparation of Leishmania sp. and T. cruzi
Soluble extracts were obtained from infective promastigotes
and epimastigotes cultures. Parasites were removed from their
respective medium by centrifugation at 500g/10 min. Pellets were
resuspended in PBS, pH 7.2; they were then centrifuged two more
times under the same conditions and further added to the ﬁnal
buffer, which contained 40 mM HEPES and 1 mM EDTA. The mate-
rial was lysed in a Dounce-type homogenizer and centrifuged at
12,500g/15 min. The supernatant was considered to be the soluble
extract that contained trypanothione reductase (TryR).24 The
whole preparation of soluble extract was carried out at 8–12 C
of temperature to avoid damage to the enzyme. The protein con-
centration of the soluble extract was assessed using a NanoDrop
1000 spectrophotometer (Thermo Scientiﬁc). All samples were ali-
quoted and stored at 70 C until analysis.
2.5. Mesoionic derivative synthesis
2.5.1. General procedure for the preparation of 4-phenyl-5-(40-
X- or 30-Y-styryl)-1,3,4-thiadiazolium-2-phenylamine chlorides
The compounds, 4-phenyl-5-(4-H-, 4-OCH3-, 3-OCH3-, or
4-NO2-styryl)-1,3,4-thiadiazolium-2-phenylamine chlorides, were
fully characterized previously,15 by infrared (IR), 1H, 13C NMR spec-
troscopy and mass spectrometry. The mesoionic derivatives were
synthesized by the coupling of the corresponding freshly prepared
40- or 30-substituted styryl chlorides (10 mmol) which were added
to a stirred solution of 1,4-diphenylthiosemicarbazide (10 mmol)
in dry 1,4-dioxane (20 mL) at room temperature. After standing
24–48 h, the products were separated by vacuum ﬁltration,
washed with dry 1,4-dioxane and recrystallized from ethanol/
dichloromethane (1:1 v/v) to yield yellow crystals.
2.6. Enzymatic assays in the soluble extract of Leishmania sp.
The capacity ofmesoionic derivatives to inhibit TryR activitywas
evaluated using the equivalent of 1 mg/mL of soluble protein ex-
tract. Four mesoionic derivatives (MI-HH; MI-3-OCH3;
MI-4-OCH3 andMI-4-NO2) were pre-incubated with the soluble ex-
tracts (derivatives at 1 lM) for 10 min, then 100 lMNADPH, 40 mM
HEPES and 1 mM EDTA, pH 7.5, was added. The assay was initiated
in a spectrophotometer (Shimadzu Corporation, Japan) at 340 nm toX = H; Y = H (MI-HH)
X = OCH3; Y = H (MI-4-OCH3)
X = H; Y = OCH3 (MI-3-OCH3)
X = NO2; Y = H (MI-4-NO2)
tives of 1,3,4 thiadiazolium-2-aminide class.
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alterations; 100 mM trypanothione disulﬁde (T(S)2, Bachem) was
then added to optimize and direct the reaction to NADPH consump-
tion by TryR. All reactionswere performed at 25 C, in a total volume
of 300 lL. After that, readings were started quickly for 100 s more.
The inhibitionpercentagewas calculated based on the decay of opti-
cal density, which reﬂects NADPH oxidation; hence, optical density
represents NADPH consumption by TryR. This decay was given for
optical density differences (DOD) after the ﬁrst 5 s after the addition
of T(S)2.24–27
2.7. Enzymatic and kinetics assays with recombinant TryR
The assay was performed with L. infantum recombinant trypan-
othine reductase (LiTryR) and T. cruzi recombinant trypanothine
reductase (TcTryR). An assay mixture consisted of LiTryR that had
been incubated with three different concentrations (0.5, 1 and
2 lM) of two mesoionic derivatives (MI-HH; 4-NO2) for 10 min.
Brieﬂy, the reaction mixtures, 40 mM HEPES, 1 mM EDTA, pH 7.5,
containing 100 lM NADPH, were prepared in a total volume of
300 lL. Those mixtures were monitored at 340 nm for 1 min until
a constant baseline was obtained, and the reaction was then
started by adding ﬁve different concentrations of T(S)2 (25, 50,
100, 200 and 500 lM). This decay was given for optical density dif-
ferences (DOD), which correlated with NADPH consumption. All
reactions were performed at 25 C and monitored with a Shimadzu
UV-2401 PC spectrophotometer (Shimadzu Corporation). Each data
set was ﬁtted by nonlinear regression to the Michaelis–Menten
equation. The resulting individual ﬁts were examined as
Lineweaver–Burk transformations, and the graphs inspected for
diagnostic inhibition patterns. The entire data set was then glob-
ally ﬁtted to the appropriate equation (competitive, mixed or
uncompetitive inhibition). The same rationale was followed for
TcTryR, but only one concentration each of the mesoionic com-
pounds (1 lM) and T(S)2 (50 lM) were used, and no enzyme ki-
netic was determined.
2.8. Molecular modeling
Molecular docking studies were implemented in order to com-
pare the interaction of the mesoionic compounds at the molecular
level with the TryR enzyme of the four parasite species: Leishmania
amazonensis, L. braziliensis, L. infantum and Trypanosoma cruzi.
2.8.1. Leishmania infantum TryR (LiTryR)
For the docking studies into the L. infantum TryR, it was used the
crystal structure obtained from Protein Data Bank site (PDB28),
with the accession code 2W0H.29 The resolution was relatively
low (3.00 Å), but this structure was chosen for having the cofactors
ﬂavin adenine dinucleotide (FAD) and nicotinamide adenine dinu-
cleotide (NADPH, in the reduced form) complexed in their respec-
tive binding sites, which are putative binding sites for the
mesoionic compounds. The binding sites are set in a more open
conformation by the presence of the cofactors, which is expected
to facilitate the docking procedure. The cofactors, water and sulfate
molecules were deleted from the 2W0H structure before the mes-
oionic compounds docking was performed.
2.8.2. Trypanosoma cruzi TryR (TcTryR)
The docking study into the T. cruzi TryR was done with the X-ray
structure deposited in PDB with accession code 1BZL.11 Water mol-
ecules were also deleted before the docking procedure.
2.8.3. Leishmania braziliensis TryR (LbTryR)
It was necessary the construction of a 3Dmodel of a L. braziliensis
TryR, because there is no crystal structure available for this protein.The primary sequence of L. braziliensis TryR was obtained in the
Swiss Prot/TrEMBL (http://www.expasy.ch/sprot/31,32) server with
the access code A4H480-1 (UniParc). The template for themodeling
procedure was the crystal structure of the L. infantum TryR com-
plexed with FAD (PDB accession code 2JK629), which was selected
with the Swiss-Model BLAST tool30 from the Swiss-Model protein-
modeling server (http://www.expasy.ch/swissmod/SWISS-MOD-
EL.html). The template protein has a 2.95 Å resolution and its
sequence identity with L. braziliensis TryR is 83,7%. Because of this
high sequence identity, we adopted a direct residues replacement
procedure with the Deep View 3.7 program33,34 on the
X-ray structure as the strategy for construction of the 3D model.
The sequences of both enzymes were aligned and L.
braziliensis TryR diverging residues with the L. infantum TryR se-
quence were then replaced with the ‘mutate’ tool. The initial rot-
amer of the mutated residues were selected in order to improve
the number or hydrogen bonds and reduce the number of atom
clashes. The ﬁnal structurewas then submitted to energyminimiza-
tion with GROMOS9635 as implemented in the ‘energy minimiza-
tion’ tool of the program.
2.8.4. Leishmania amazonensis TryR (LaTryR)
There is no crystal structure available for this protein, as
L. braziliensis TryR. We employed the model obtained previously
by our group25 using the Crithidia fasciculata TryR (PDB accession
code 1FEC48) X-ray structure as a template.
Ligand structures were energy minimized with the PM3
semiempirical method36 available in the Spartan’08 program
(Wavefunction, Inc.) and saved in the SYBYL MOL2 ﬁle format.
The docking of the ligands into the TryR structures was imple-
mented with the GOLD 5.0 program (CCDC Software Ltd), an
efﬁcient genetic algorithm for docking ﬂexible ligands into protein
binding sites. Hydrogen atoms were added to the proteins based on
ionization and tautomeric states inferred by the program. The
number of genetic operations (crossover, migration, mutation) in
each run during the searching procedure was set to 100.000. The
program optimizes hydrogen-bond geometries by rotating hydro-
xyl and amino groups of amino acid side chains. All scoring func-
tions available in the program were used for calculations:
GoldScore,37 ChemScore,38 ASP39 and ChemPLP.40,41
The TryR contains a active binding site for T(S)2 and two alloste-
ric binding sites for NADPH and FAD binding, which were also ex-
plored in the docking procedure. The binding site was deﬁned with
a 20 Å radius from selected residues located at the center of each
site. In the active binding site, the mesoionic compounds were
docked containing T(S)2 at the same time, because it was deter-
mined experimentally that the inhibition was non-competitive.
The three binding sites residues were analyzed and compared be-
tween the L. amazonensis, L. braziliensis, L. infantum and T. cruzi en-
zymes, looking for explanations for activity differences between
the compounds under study.2.9. Statistic analysis
Signiﬁcance was determined using a non-paired Student’s T-
test. Differences were considered to be signiﬁcant when p <0.05.
Each experiment was performed in triplicate.
3. Results
3.1. Trypanothione reductase activity assay in soluble parasite
extracts
The aimof the assaywas to determine the effect of fourmesoion-
ic derivatives on TryR activity. Initially, this effect was evaluated in
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promastigotes (Fig. 2A). The reaction was followed by NADPH con-
sumption in the presence/absence of the compounds, 5 s after T(S)2
addition. The control (in the absence of mesoionic derivatives) was
considered to be 100% TryR activity. The addition of mesoionic
derivatives (MI-HH, MI-4-OCH3 and MI-3-OCH3) did not modify
NADPH consumption in this TryR activity assay, except the deriva-
tive MI-4-NO2 (1 lM), which was able to inhibit 76% (p <0.005) of
NADPH consumption by L. amazonensis extracts compared with
the control. Therefore, the same assay was carried out with other
soluble extracts from the other parasites, using the late log phase
of L. infantum, L. braziliensispromastigotes and T. cruzi epimastigotes
(Fig. 2B).MI-4-NO2 at 1 lMwas able to inhibit NADPH consumption
by TryR in parasites extracts, at 70% in L. infantum, 69.5% in L. brazili-
ensis and 83% in T. cruzi (p <0.005). These results strongly indicate
that TryR could be a target for MI-4-NO2. The same assay was also
performed with MI-HH, as benchmark.
3.2. Trypanothione reductase activity assay in recombinant
enzymes from L. infantum and T. cruzi
From the results obtained from the TryR activity assay in solu-
ble extracts of parasites, NADPH consumption assays were con-
ducted using recombinant enzymes from L. infantum (LiTryR) and
T. cruzi (TcTryR). These assays were followed for 100 s, in which
NADPH consumption was analyzed after the addition of 50 lM
T(S)2 to the reaction mixture. It is important to note that up to
60 s of evaluation, there was no consumption or any signiﬁcantFigure 2. TryR inhibition in soluble extracts from parasites by mesoionic deriva-
tives at 1 lM concentration. NADPH consumption by TryR activity was evaluated
after 500 of T(S)2 addition; control means the maximum amount of NADPH
consumption in soluble extract (⁄p <0.005). A. NADPH consumption by TryR in
L. amazonensis extract in the presence of all compounds. B. NADPH consumption by
TryR in different parasite extracts of Leishmania promastigotes and epimastigotes of
T. cruzi in the presence of MI-HH and MI-4-NO2.change in the NADPH amount before the addition of substrate
(Fig. 3). After this addition, a fast NADPH consumption in the ﬁrst
5 s of reaction was observed. In parallel, assays were conducted in
the presence of DMSO, for which no signiﬁcant changes were
observed in NADPH consumption. Pre-incubation of 1 lM of MI-
4-NO2 with both LiTryR and TcTryR signiﬁcantly decreased the
absorbance decay in the ﬁrst 5 s, with inhibition of 76% of LiTryR
and 69% of TcTryR (p <0.005). The addition of 1 lM of MI-HH did
not alter NADPH consumption in comparison with the control.
The enzyme kinetics of LiTryR were analyzed to conﬁrm the
mode of action of MI-4-NO2 and MI-HH. Three concentrations were
used for both compounds. The rates of such enzyme reactions
could be analyzed by the Michaelis–Menten approach and algebra-
ically transformed into forms that are more useful in practical
studies. For that reason, these kinetic data are shown in the Fig-
ure 4 as a Lineweaver–Burk graph. In Figure 4A, the MI-4-NO2
derivative was used as the LiTryR inhibitor on enzyme kinetics,
effectively decreasing their activity. This effect on the enzyme
was demonstrated by lower values of Vmax (maximum reaction
rate; graph vertical axis) and little or no apparent effect on Km
(Michaelis constant; graph horizontal axis), which are the charac-
teristic effects of a noncompetitive inhibition. The IC50 (inhibition
concentration 50%) for LiTryR was estimated in 1.63 ± 0.06 lM to
MI-4-NO2. However, as Figure 4B shows, there were no alterations
when the three concentrations of MI-HH were tested in the same
assay with LiTryR.3.3. Docking studies
In order to identify at the molecular level possible reasons for
the different enzyme inhibition proﬁles of the mesoionic com-
pounds, a docking study with the TryR of the four parasite species
was implemented. The molecules were evaluated in the neutral
form, because of the conditions used in the experimental proce-
dure (neutral pH). As TryR is a FAD-dependent oxidoreductase,
which utilizes NADPH as an electron donor, it contains binding
sites for FAD and NADPH, besides the substrate binding site. All
four docking functions were able to effectively dock these ligands
into their respective binding sites. We present here the results ob-
tained with one of these functions, ASP. ASP is an atom–atom po-
tential derived from a database of protein–ligand complexes and
it was demonstrated to predict the correct binding modes of a list
of 139 druglike compounds with a success rate of 72%.39
The ﬁrst site investigated with the docking method was the
substrate binding site. Since the kinetic data indicated a non-com-
petitive LiTryR inhibition proﬁle by MI-4-NO2, docking runs were
also performed with the TSST binding site containing the substrate
molecule. A number of poses for each ligand were obtained and
scored and the best-ranked pose in each TryR was chosen for fur-
ther analysis. The ﬁtness functions of the GOLD program give ﬁt-
ness scores that are dimensionless. In each case, the scale of the
score is a guide of how good the docking pose is; the higher the
score, the better the docking result probably is. The docking results
are summarized on Table 1.
Next, docking runs were implemented into the TryR FAD and
NADPH allosteric binding sites. Because of the close proximity be-
tween both sites, it was necessary to previously dock the FAD mol-
ecule into its binding site before the docking runs of the ligands
into the NADPH binding site were executed; similarly, the ligands
were docked into the FAD binding site of the NADPH/TryR binary
complex. In addition, as the substrate could possibly exert some
inﬂuence in the docking of the mesoionic compounds into the
FAD binding site due to its closeness to the TSST binding site, we
also made docking runs with the enzyme containing both TSST
and NADPH (Table 2).
Figure 3. LiTryR and TcTryR inhibition by MI-4-NO2. Activity of TryR on T(S)2 (50 lM), followed by monitoring NADPH consumption at 340 nm. The reaction mixture
contained NADPH, TryRs and MI derivatives. The arrow indicates the moment when T(S)2 was added after 60 s of monitoring. The mesoionic derivatives tested were MI-4-
NO2 (triangles and black circles) and MI-HH (asterisks and squares). Controls are gray circles for LiTryR and gray diamonds for TcTryR. Controls without enzyme (LiTryR or
TcTryR) using MI compounds are dashed lines, MI-4-NO2 (black triangles) and MI-HH (gray asterisks).
Figure 4. Kinetic analysis of LiTryR activity. The enzyme concentration was
maintained as a constant, while substrate [T(S)2] and compounds varied, as
follows: (A) MI-4-NO2, no addition (diamonds); 0.86 lM (squares); 1.72 lM
(triangles); 3.44 lM (asterisks), IC50 = 1.63 ± 0.06; (B) MI-HH, no addition (dia-
monds); 0.86 lM (squares); 1.72 lM (triangles); 3.44 lM (circle), IC50 = not
determined.
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Synthetics compounds or compounds from natural sources have
been investigated as selective inhibitors of trypanothione reduc-
tase in several previous studies.11,26,41,24,23,42 Trypanosomatids
possess a unique thiol metabolism based on trypanothione–trypa-
nothione reductase, which plays a crucial role in regulating the re-
dox balance and the defense against oxidative stress in a pathway
not shared by the human host.10 In the present study, we investi-
gated the effect of four mesoionic compounds (MI-HH, MI-4-NO2,
MI-4-OCH3 and MI-3-OCH3) in in vitro assays as potential inhibi-
tors of trypanothione reductase. Among the four tested com-
pounds, only MI-4-NO2 showed an enzyme inhibition effect on
the four extracts assayed. This inhibition assay using MI-4-NO2
was also performed on recombinant enzymes from T. cruzi and L.
infantum. The best activity of MI-4-NO2 could be related to phar-
macokinetic and pharmacodynamic parameters,43 which were
not studied in this work. The enzyme kinetics determined with
LiTryR demonstrated a non-competitive inhibition proﬁle by
MI-4-NO2.
The four mesoionic compounds were predicted to effectively
dock into the substrate binding site, independently of the species,
but only in the binary complexes MI-4-NO2 is predicted as the best
ligand for the TryR of all four parasite species. Because the sub-
strate binding site is quite large, both substrate and mesoionic
compound could be also accommodated simultaneously into the
cavity forming ternary complexes. However, the presence of the
substrate was deleterious for the mesoionic compounds binding,
as can be observed by the lowering of their respective ﬁtness
scores; besides, differently from the binary complexes, now
MI-4-NO2 was not predicted as the best ligand. MI-3-OCH3 was
predicted as the best ligand for LaTryR andMI-4-OCH3 for the other
parasites, which is not in accordance with the experimental data.
These results are suggestive that the activity of the mesoionic
compounds could be related to the binding to another TryR binding
site; interestingly, recent results obtained by Bilia and co-workers
indicated that naphthodianthrone inhibitors of thioredoxin
Table 2
Docking results into the FAD and NADPH binding sites
Ligand NADPH binding sitea,b FAD binding sitea,c FAD binding sitea,d
LaTryR LiTryR LbTryR TcTryR LaTryR LiTryR LbTryR TcTryR LaTryR LiTryR LbTryR TcTryR
MI-HH 29.12 37.3 31.41 29.92 26.02 34.18 28.55 18.22 20.54 19.56 22.09 22.53
MI-3-OCH3 30.11 34.6 32.2 29.69 26.99 29.69 30.44 13.66 20.97 20.81 22.75 22.98
MI-4-NO2 30.67 42.38 36.49 32.35 29.81 27.81 33.67 24.73 23.35 23.55 25.38 24.64
MI-4-OCH3 32.47 40.76 34.5 30.58 25.74 28.18 30.69 20.04 24.41 19.86 24.29 24.54
FAD 56.45 71.02 65.18 77.93
NADPH 41.44 54.76 44.85 40.96
a Fitness scores, ASP function.
b Docking of the ligands into the NADPH binding site of the FAD–TryR binary complex.
c Docking of the ligands into the FAD binding site of the NADPH–TryR binary complex.
d Docking of the ligands into the FAD binding site of the NADPH–TSST–TryR ternary complex.
Table 1
Docking results in the TSST binding site
Ligand Binary complexesa Ternary complexesa,b
LaTryR LiTryR LbTryR TcTryR LaTryR LiTryR LbTryR TcTryR
MI-HH 28.12 28.87 28.63 29.21 20.17 18.63 20.33 21.20
MI-3-OCH3 29.65 30.24 32.05 32.64 25.44 21.12 22.15 22.91
MI-4-NO2 32.29 32.31 33.74 33.60 23.88 20.25 24.10 23.09
MI-4-OCH3 30.59 29.55 31.94 31.41 23.87 21.77 23.68 24.62
TSST 32.36 36.06 32.28 38.58
a Fitness scores, ASP function.
b Docking of the ligands together with the substrate in the binding site.
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binding site.44 It can be observed in Table 2 that the ligands can
dock favorably into de FAD binding site, but the presence of TSST
in the adjacent binding site inﬂuenced unfavorably the docking
of the ligands, as can be seen by the score values listed in Table
2. The docking of the mesoionic compounds into the NADPH site,
however, was predicted as better than into the FAD site, and also
than in the TSST site (Table 1). The docking results show addition-
ally that MI-4-NO2 is predicted as the best ligand of the NADPH
binding site for three of the parasite species (it is the second best
ligand for LaTryR).
Figure 5 (A and B) presents a superimposition of the best dock-
ing poses of the mesoionic compounds inside the LiTryR NADPHFigure 5. (A) Superposition of the best poses of the three inactive mesoionic compounds
MIHH: cyan; FAD: orange, TryR: green. (B) Superposition of the best poses of the active m
MI-4NO2: purple; NADPH: yellow; FAD: orange, TryR: green. Hydrogen atoms were rembinding site. All compounds occupy the same binding site, but with
different orientations. The nitro group of MI-4-NO2 makes a H
bond with Lys60 side chain (O  N distance of 3.47 Å); the planar-
ity of the nitro group apparently helps the p-nitro-phenyl group to
make p–p interactions with the isoalloxazine ring of the FAD co-
factor, which is responsible for its redox behavior, so it is expected
that these interactions could interfere with the enzyme activity
(Fig. 5B). This is not the case of the methoxy substituent, and the
p-methoxy-phenyl and the m-methoxy-phenyl substituents of
MI-4-OCH3 and MI-3-OCH3, respectively, are turned to the oppo-
site side in the best poses identiﬁed by the docking procedure
(Fig. 5A). These observations explain the best score of the MI-4-
NO2 and could be related to its experimental inhibitory activity.in LiTryR NADPH binding site. Carbon atoms: MI-3OCH3: magenta; MI-4OCH3: pink;
esoionic compound and of NADPH in the LiTryR NADPH binding site. Carbon atoms:
oved to improve clarity.
1766 R. F. Rodrigues et al. / Bioorg. Med. Chem. 20 (2012) 1760–17665. Conclusion
Although the triage of mesoionic compounds via the TryR assay
has resulted in the identiﬁcation of MI-4-NO2 as the only active en-
zyme inhibitor, potent antiparasitic activities have been shown for
all mesoionic compounds tested here. Regardless of the mecha-
nism of action, the observation of potent antiparasitic activity for
the mesoionic compounds is interesting and potentially therapeu-
tically relevant. Other mechanisms of action of mesoionic deriva-
tives, independent of TryR inhibition, remain to be established. It
is possible that more than one metabolic pathway in the parasites
is involved. Mesoionic compounds, similar to other compounds ci-
ted in the scientiﬁc literature, are clearly not ‘magic bullets’ that
speciﬁcally inhibit one target45; instead, they take advantage of
‘polypharmacology’.46,47 The results obtained in this work will be
useful for future studies of mesoionic compounds as part of a drug
discovery program against Leishmaniasis or Chagas’ disease.
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